Home / Nieuws / ...

 

Rozemarijn en uw ogen*
Uit een studie zowel in het laboratorium als met knaagdieren blijkt dat rozemarijn goed kan zijn voor gezonde ogen. Eerdere studies lieten al zien dat rozemarijn vrije radicalenschade in de hersenen kan aanpakken. Uit deze studie blijkt de bioactieve stof carnosinezuur in rozemarijn (ook te vinden in echte salie) de retina kan beschermen tegen vrije radicalenschade zoals bij macula degeneratie. Bij de knaagdieren bleek carnosinezuur te zorgen voor bescherming en het beter functioneren van de lichtgevoelige cellen in het netvlies.
In Laboratory Model, Compound Found In Rosemary Protects Against Macular Degeneration
Herbs widely used throughout history in Asian and early European cultures have received renewed attention by Western medicine in recent years. Scientists are now isolating the active compounds in many medicinal herbs and documenting their antioxidant and anti-inflammatory activities. In a study published in the journal Investigative Ophthalmology & Visual Science, Stuart A. Lipton, M.D., Ph.D. and colleagues at Sanford-Burnham Medical Research Institute (Sanford-Burnham) report that carnosic acid, a component of the herb rosemary, promotes eye health. 
Lipton's team found that carnosic acid protects retinas from degeneration and toxicity in cell culture and in rodent models of light-induced retinal damage. Their findings suggest that carnosic acid may have clinical applications for diseases affecting the outer retina, including age-related macular degeneration, the most common eye disease in the U.S. 
Age-related macular degeneration 
Age-related macular degeneration likely has many underlying causes. Yet previous studies suggest that the disease might be slowed or improved by chemicals that fight free radicals - reactive compounds related to oxygen and nitrogen that damage membranes and other cell processes. 
Lipton's team first discovered a few years ago that carnosic acid fights off free radical damage in the brain. In their latest study, Lipton and colleagues, including Tayebeh Rezaie, Ph.D. and Takumi Satoh, Ph.D., initially investigated carnosic acid's protective mechanism in laboratory cultures of retinal cells. 
The researchers exposed the cells growing in the dish to hydrogen peroxide in order to induce oxidative stress, a factor thought to contribute to disease progression in eye conditions such as macular degeneration and retinitis pigmentosa. They found that cells treated with carnosic acid triggered antioxidant enzyme production in the cells, which in turn lowered levels of reactive oxygen and nitrogen species (cell-damaging free radicals and peroxides). 
Rosemary's therapeutic potential 
Lipton, Rezaie, Satoh and colleagues next tested carnosic acid in an animal model of light-induced damage to photoreceptors - the part of the eye that converts light to electrical signals, enabling visual perception. As compared to the untreated group, rodents pre-treated with carnosic acid retained a thicker outer nuclear layer in the eye, indicating that their photoreceptors were protected. The carnosic acid-treated rodents also exhibited better electroretinogram activity, a measure of healthy photoreceptor function. 
What's next for carnosic acid? "We're now developing improved derivatives of carnosic acid and related compounds to protect the retina and other brain areas from a number of degenerative conditions, including age-related macular degeneration and various forms of dementia," said Lipton, director of Sanford-Burnham's Del E. Webb Neuroscience, Aging, and Stem Cell Research Center and an active clinical neurologist. 
References:
This research was funded by the U.S. National Institutes of Health: Eunice Kennedy Shriver National Institute of Child Health & Human Development grant P01 HD29587; National Institute of Environmental Health Sciences grant P01 ES016738; National Institute of Neurological Disorders and Stroke grant P30 NS076411; National Eye Institute grant R01 EY05477 
The study was co-authored by Tayebeh Rezaie, Sanford-Burnham; Scott R. McKercher, Sanford-Burnham; Kunio Kosaka, Nagase & Co., Ltd.; Masaaki Seki, Sanford-Burnham; Larry Wheeler, Allergan, Inc.; Veena Viswanath, Allergan, Inc.; Teresa Chun, Allergan, Inc.; Rabina Joshi, Sanford-Burnham; Marcos Valencia, Sanford-Burnham; Shunsuke Sasaki, Iwate University; Terumasa Tozawa, Iwate University; Takumi Satoh, Sanford-Burnham and Iwate University; and Stuart A. Lipton, Sanford-Burnham. (December 2012)



Printen

 

 

Reacties: